Who's a EUFLEXXA candidate?

The EUFLEXXA TRIFECTA can benefit a range of patients with OA knee pain
THE BYSTANDER

Patients who have cut back or stopped participating in daily activities they used to enjoy.

THE PHYSICAL THERAPY NON-RESPONDER

Patients for whom physical therapy is no longer effective or is simply not an option.

THE TOLERATOR

Patients who have accepted OA knee pain as an inevitable part of everyday life because remedies such as ice packs, heating pads, or lifestyle interventions such as weight loss or exercise have run their course.

THE OTC FAILURE

When simple pain relievers, such as acetaminophen, can longer provide adequate pain relief.

THE AVOIDER

Patients with OA knee pain who are not candidates for other types of treatment.

Please See Important Safety Information and Full Prescribing Information.

INDICATION

EUFLEXXA® [1% sodium hyaluronate] is indicated for the treatment of pain in osteoarthritis [DA] of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics [eg, acetaminophen].

IMPORTANT SAFETY INFORMATION

EUFLEXXA is contraindicated in patients who have a known hypersensitivity to hyaluronate preparations or who have knee joint infections, infections, or skin disease in the area of the injection site.

EUFLEXXA should not be administered through a needle previously used with medical solutions containing benzalkonium chloride. Do not use skin disinfectants for skin preparation that contain quaternary ammonium salts.

Do not inject intravascularly due to potential for systemic adverse events.

The safety and effectiveness of injection in conjunction with other intra-articular injectables, or into joints other than the knee have not been studied. Remove any joint effusion prior to injecting. Transient pain or swelling of the injected joint may occur after intra-articular injection with EUFLEXXA.

The most common adverse events related to EUFLEXXA injections reported in 12- and 26-week clinical studies were arthralgia, back pain, pain in extremity, musculoskeletal pain, and joint swelling. In an open-label extension of the 26-week clinical study with repeat series of injections, the most common adverse events related to EUFLEXXA at Week 52 were arthralgia and joint swelling.

Please see Full Prescribing Information.

Please see Full Prescribing Information.